Management
Lyndon Lien, Ph.D.
Co-founder & Advisor

Lyndon serves as Advisor and member of the Board of Directors for Balance Therapeutics. Previously he was President, Chief Executive Officer and Co-founder of Balance Therapeutics and provided overall leadership for the company for over 8 years. Lyndon is an Operating Partner with Nan Fung Life Sciences and Pivotal bioVenture Partners where he invests in, manages and builds transformational life sciences companies. Prior to Balance Therapeutics, Lyndon was Vice President of Corporate Strategy and Alliances at Elan Pharmaceuticals and was responsible for strategic planning, product planning and business development. As Director of Technology Planning at ALZA, a specialty pharmaceutical company of Johnson & Johnson, he led technology strategy and guided new product planning teams. He was a Principal at the venture capital company Coastview Capital and led and supported successful investments in early stage biopharmaceutical and research tool companies. He was also a management consultant at McKinsey & Company and a leader in the Pharmaceutical and Medical Products Practice. He provided direction to senior executives of leading healthcare companies on business strategy, R&D strategy, operations, new business creation, mergers/acquisitions, and product commercialization.

Lyndon has an A.B. in Biochemical Sciences from Harvard University, an M.B.A. from MIT Sloan School of Management and a Ph.D. in Genetics from Harvard University.

 
Morgan Lam
Chief Operating Officer

Morgan serves as Chief Operating Officer and is responsible for leading operations and development of product BTD-001. Previously, he was the Chief Operating Officer and Senior Vice President of Development for Humanigen Inc. (formerly KaloBios Inc) from January 2016 to 2018 where he was responsible for the development of lenzilumab and ifatuzumab for various oncology and non-oncology indications. Prior to that, he served as Executive Director for Medical & Scientific Affairs for Geron Corp. as well as Head of Clinical Operations Department from 2010 to 2015 where he played a key role in the development of imetelstat. Prior to that, Morgan spent six years at Genentech Inc. (now Hoffman LaRoche) as Clinical Program Manager in leading the clinical operations efforts for numerous oncology drug candidates including Gazyva® and Venclexta for the treatment for various solid and liquid tumors. Before Genentech, he worked with increasing responsibilities for over six years in the Clinical Development organizations for INEX and QLT Inc.

Morgan received his bachelor’s degree in Microbiology and Biochemistry from the University of British Columbia and currently participates in various executive leadership and entrepreneurship programs.

 
Alejandro Dorenbaum, M.D.
Head of Clinical Development

Alejandro (Alex) serves as Head of Clinical Development. Previously, he was Chief Medical Officer at Allakos Pharmaceutical where he achieved proof-of-concept in clinical trials for novel therapeutic antibodies targeting inflammatory cells. He served as Chief Medical Officer at Lumena Pharmaceutical until it's acquisition by Shire. Prior to that, Alex joined Genentech, where he was responsible for the respiratory programs for asthma and cystic fibrosis, BioMarin Pharmaceutical, Inc. where he conducted the clinical development of Kuvan® and Chiron Corporation where he acquired broad expertise in several areas of drug development including biologics, small molecules, and vaccines. Alex consults for several early development companies and he maintains an active academic position as Clinical Professor of Pediatrics at Stanford University School of Medicine, where he treats patients with Allergy and Immunology clinical problems.

 
Xiao-Xiong Lu, Ph.D.
Vice President of Technical Operations

Xiao-Xiong serves as Vice President of Technical Operations responsible for all aspects of pharmaceutical CMC development, manufacturing and supply chain. He has 30 years of experience in the US pharmaceutical and related industries having worked at both large pharma and small to medium biotech companies. He has consulted for a number of biotech and pharmaceutical companies in the areas of CMC and business development. From 2003 to 2015, he was with Arena Pharmaceuticals, most recently as Associate VP of CMC Technical Operations as well as Managing Director for Greater China. From 1990 to 2003, he worked at Monsanto Company and its spin-off Solutia Inc. with increasing responsibilities in R&D and manufacturing.

Xiao-Xiong received his PhD in Chemical Engineering from University of Birmingham in the UK and has taken MBA courses at Louisiana State University.

 

Management also works closely with a team of consultants and partners across key functions including manufacturing, preclinical toxicology, clinical development, clinical operations, data management, statistics, quality and regulatory affairs.